Product
Recombinant Herpes Zoster Vaccine
2 clinical trials
2 indications
Indication
Herpes ZosterIndication
Vaccine-Preventable DiseasesClinical trial
A Phase II, Single Center, Randomized, Blind, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and AboveStatus: Active (not recruiting), Estimated PCD: 2024-02-28
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety, and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Subjects Aged 40 Years and OlderStatus: Recruiting, Estimated PCD: 2024-12-31